🏢 官网IRGERNDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:00:13(美东 08:00)·⟳ 抓取 20:01:03回填·⚡ 决策 10-21 20:02:50 +2m37s·6.2 天前
Geron公告将于2026年11月4日盘前发布Q3财报，纯日程通知无业绩数据
本稿是例行财报发布日期与电话会议安排（save-the-date），不含收入、利润、指引、订单或临床读数等任何可重定价的新事实，属市场可预期的程序性事件，方向不明、无交易edge；实质催化在2026-11-04盘前的实际财报，届时应作为独立事件研判。
📄 原文GERN↗ 原文
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharma…
不做 Geron Corporation（GERN.US）
纯财报发布日期与电话会议日程通知，无收入、利润、指引或临床数据等任何增量信息，属预期内程序性事件，无方向性edge；真正催化在2026-11-04盘前实际财报，届时再独立研判，不在日程稿上提前建仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Geron仅公告Q3财报将于11月4日盘前发布并附电话会议安排，无任何业绩数字或经营增量，属中性程序性日程通知，不具备可交易预期差，故回避，等待财报日实际数据。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 low · price-in 风险 low ↗
主要风险
- 若11月4日财报披露RYTELO销售或imetelstat骨髓纤维化III期数据超/低于预期，将构成独立催化，需届时另行研判，本日程稿不提供该信息。
先例如何影响了这次决策
对本次决策的影响:确认不在日程公告上建仓，等待11月4日实际财报作为独立事件再研判。
方向:无可对照的同类价格先例；财报日期预告为程序性事件，不构成方向性催化，无需以先例校准幅度。
涨幅量级:无业绩增量，不设定止盈/止损幅度。
形态:save-the-date类公告本身通常不引发独立重定价；实质波动发生在财报实际披露时。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 3,032 ms
{"result": "search_processed_events:agent query=`gern imetelstat rytelo 业绩公布日程 | geron q3 2026 financial results november 4 conference call | geron 第三季度2026财报发布日期 11月4日`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、22528 条本臂决策(完整)，返回 3 条候选。\n• 10-20 20:35 UTC(北京 10-21 04:35) [bm25:43%] 不做 GT.US (wire) — Good
原文全文
展开原文 · 1,717 字
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the
Investors
section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available through the Investors section of the Company’s website at
www.geron.com
.
About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit
www.geron.com
or follow us on
LinkedIn
.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
Investors
section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available through the Investors section of the Company’s website at
www.geron.com
.
About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit
www.geron.com
or follow us on
.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
8fa08e66ce· 2026-10-21 20:02 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前